Neumora Therapeutics, Inc. - 10-Q Filing
Neumora Therapeutics filed its 10-Q for the quarter ended March 31, 2026, disclosing financial results and operational updates. The company reported a net loss of $29.8 million for the first quarter of 2026, compared to a net loss of $24.5 million in the same period in 2025. Total operating expenses increased to $30.1 million from $24.8 million year-over-year, primarily due to higher research and development costs. The filing also outlined ongoing agreements, including a loan and security agreement with K2 Health Ventures LLC and a Parkinson’s Research Ventures funding agreement.
Tickers: $NMRA